抗血小板治疗下机器人肝切除术的安全性:倾向性评分匹配研究
该回顾性研究评估了2013至2025年间在本机构接受择期机器人肝切除术的患者,比较继续抗血小板治疗者与对照组的出血和缺血事件。经1:1倾向性评分匹配后各46例,两组在估计失血量>500 mL、术后肝切除出血、术后出血事件、院内死亡及缺血事件上均无显著差异,支持围术期继续抗血小板治疗。
要点
- 匹配后抗血小板组与对照组出血及缺血事件无显著差异。
- 机器人肝切除术中继续抗血小板治疗未增加术后出血风险。
- 研究支持在维持抗血小板治疗的患者中安全实施机器人肝切除术。
核心结论
- 继续抗血小板治疗与机器人肝切除术患者术中及术后出血或缺血事件无关,支持围术期继续用药。
研究设计与样本
- 回顾性队列研究,纳入2013至2025年在本机构接受机器人肝切除术的患者,抗血小板组62例与对照组594例,经1:1倾向性评分匹配后各46例。
主要发现
- 匹配后抗血小板组与对照组估计失血量>500 mL发生率分别为6.1%与6.5%(p=0.784;OR 1.07,95%CI 0.37-3.11,p=0.903)。
- 术后肝切除出血发生率分别为2.2%与3.2%(p=0.644;OR 1.49,95%CI 0.33-6.76,p=0.622)。
- 术后出血事件发生率分别为3.4%与6.5%(p=0.272;OR 1.98,95%CI 0.65-5.99,p=0.259)。
- 院内死亡率分别为0.8%与3.2%(p=0.135;OR 3.93,95%CI 0.75-20.68,p=0.149)。
- 缺血事件发生率分别为1.5%与3.2%(p=0.279;OR 2.17,95%CI 0.46-10.26,p=0.368)。
临床怎么用
- 对于接受抗血小板治疗且需行择期机器人肝切除术的患者,围术期可考虑继续抗血小板治疗而不必常规停药。
局限性
- 本研究为单中心回顾性分析,样本量有限,匹配后每组仅46例,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiplatelet (AP) therapy is increasingly prescribed for secondary and primary cardiovascular prevention. Liver resection (LR) is inherently associated with moderate-to-high risk of bleeding, while AP therapy discontinuation may increase the incidence of thrombotic events. Evidence regarding the safety of continuing AP therapy during robotic LR is limited. The aim of this study was to assess hemorrhagic and ischemic events in patients undergoing elective robotic LR and their association with AP continuation. METHODS: Patients who underwent robotic LR at our institution between 2013 and 2025 were retrospectively evaluated. Patients receiving AP therapy were compared with controls, both before and after 1:1 propensity score matching (PSM). Primary endpoints included in-hospital mortality, estimated blood loss (EBL) > 500 mL, post-hepatectomy hemorrhage (PHH), postoperative bleeding events, and ischemic events. Associations between AP continuation and intra- and postoperative outcomes were assessed through univariate analysis. RESULTS: Before matching, 62 patients were included in the AP group and 594 in the control group. Age, diabetes, cardiovascular comorbidities, Charlson Comorbidity Index, and MELD score were significantly higher in the AP cohort. After PSM, 46 patients were included in each group. No significant differences were observed between AP and control groups in EBL > 500 mL (6.1% vs. 6.5%, p = 0.784; OR 1.07, 95% CI 0.37-3.11, p = 0.903), PHH (2.2% vs. 3.2%, p = 0.644; OR 1.49, 95% CI 0.33-6.76, p = 0.622), postoperative bleedings (3.4% vs. 6.5%, p = 0.272; OR 1.98, 95% CI 0.65-5.99, p = 0.259), in-hospital mortality (0.8% vs. 3.2%, p = 0.135; OR 3.93, 95% CI 0.75-20.68, p = 0.149), or ischemic events (1.5% vs. 3.2%, p = 0.279; OR 2.17, 95% CI 0.46-10.26, p = 0.368). CONCLUSIONS: Continuation of antiplatelet therapy was not associated with intra- and postoperative bleedings or ischemic events in our cohort. These findings suggest that robotic LR is safe in patients maintained on AP agent and support its perioperative continuation.
引用
- Esposito G, Manicardi M, Ross S, et al. Safety of robotic liver resection under antiplatelet therapy: a propensity score-matching study. Surg Endosc. 2026. PMID: 42536087. doi:10.1007/s00464-026-13226-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。